Scholarlink

Background <p>Hepatitis B virus (HBV) infection remains one of the most common infectious diseases globally and can be exacerbated by coinfection with hepatitis D virus (HDV). In Germany, the incidence of hepatitis is reported annually through mandatory notification data. Nevertheless, these data lack information on hepatitis prevalence and testing coverage. We evaluated whether statutory health insurance claims data are suitable for continuous monitoring of key hepatitis indicators and whether they can complement existing HBV and HDV surveillance with reliable, population-based estimates.</p> Methods <p>We conducted a population-based cohort study using anonymised claims data from an age- and gender-representative sample from the InGef (Institute for Applied Health research) database between 2016 and 2021. We retrospectively analysed monitoring indicators for HBV and HDV -including annual prevalent infections within the respective analysis year, incidence of newly detected HBV infections (defined using a 3-year diagnosis-free interval) and the number of persons tested- based on coded diagnoses among individuals with access to healthcare services. Results were extrapolated to the German total population.</p> Results <p>Between 1,996 and 2,066 persons per 100,000 population were tested annually for at least one HBV marker (HBsAg or Anti-HBc), with 97% undergoing HBsAg testing only. The proportion of annual prevalent HBV infections ranged from 0.14% to 0.15% between 2016 and 2020. Incidence of newly detected HBV infections (3-year diagnosis-free interval) declined from 13.5 per 100,000 in 2019 to 8.9 per 100,000 in 2020. The proportion of prevalent HDV infections among HBV-positive persons varied from 4.5 to 6.4%.</p> Conclusions <p>Claims data provide a viable basis for continuous monitoring of selected hepatitis indicators in Germany. The number of prevalent and incident infections is consistent with other data sources and we were able to estimate the number of persons tested for hepatitis, addressing an important data gap. Claims data complement current surveillance systems and provide information for targeted public health action. The established approach should be applied to generate further hepatitis monitoring indicators.</p> Trial registration <p>Clinical trial number: Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Generating hepatitis B and D monitoring indicators in Germany using claims data: number of persons tested, incident and prevalent infections, 2016–2021

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Lisa Branke,
  • Alexandra Hofmann,
  • Anastassiya Stepanovich-Falke,
  • Marco Alibone,
  • Viviane Bremer,
  • Ruth Zimmermann,
  • Sandra Dudareva

摘要

Background

Hepatitis B virus (HBV) infection remains one of the most common infectious diseases globally and can be exacerbated by coinfection with hepatitis D virus (HDV). In Germany, the incidence of hepatitis is reported annually through mandatory notification data. Nevertheless, these data lack information on hepatitis prevalence and testing coverage. We evaluated whether statutory health insurance claims data are suitable for continuous monitoring of key hepatitis indicators and whether they can complement existing HBV and HDV surveillance with reliable, population-based estimates.

Methods

We conducted a population-based cohort study using anonymised claims data from an age- and gender-representative sample from the InGef (Institute for Applied Health research) database between 2016 and 2021. We retrospectively analysed monitoring indicators for HBV and HDV -including annual prevalent infections within the respective analysis year, incidence of newly detected HBV infections (defined using a 3-year diagnosis-free interval) and the number of persons tested- based on coded diagnoses among individuals with access to healthcare services. Results were extrapolated to the German total population.

Results

Between 1,996 and 2,066 persons per 100,000 population were tested annually for at least one HBV marker (HBsAg or Anti-HBc), with 97% undergoing HBsAg testing only. The proportion of annual prevalent HBV infections ranged from 0.14% to 0.15% between 2016 and 2020. Incidence of newly detected HBV infections (3-year diagnosis-free interval) declined from 13.5 per 100,000 in 2019 to 8.9 per 100,000 in 2020. The proportion of prevalent HDV infections among HBV-positive persons varied from 4.5 to 6.4%.

Conclusions

Claims data provide a viable basis for continuous monitoring of selected hepatitis indicators in Germany. The number of prevalent and incident infections is consistent with other data sources and we were able to estimate the number of persons tested for hepatitis, addressing an important data gap. Claims data complement current surveillance systems and provide information for targeted public health action. The established approach should be applied to generate further hepatitis monitoring indicators.

Trial registration

Clinical trial number: Not applicable.